Viking Therapeutics, Inc. (VKTX) Stock Overview
Explore Viking Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Viking Therapeutics, Inc. (VKTX)
Key Financials
Key Financials
Market Cap
4B
P/E Ratio
-8.40
EPS (TTM)
$-4.14
ROE
-0.71%
VKTX Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Viking Therapeutics, Inc. (NASDAQ: VKTX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Viking Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of VKTX on the NASDAQ shows an RSI of 45.29, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $34.24 for the NASDAQ listing.
Key metrics behind Viking Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of -8.40 and a market capitalization of 4B. Combined with our AI analysis, these give both institutional and retail investors a clear view of VKTX on the NASDAQ.